Alnylam Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
ALNY Alnylam Pharmaceuticals Inc
NUV Nuveen Municipal Value Fund
NNBR NN Inc
WAT Waters Corp
ADP Automatic Data Processing Inc
CLABF Core One Labs Inc
FRHLF Freehold Royalties Ltd
WDAY Workday Inc
ENVX Enovix Corp
ENB Enbridge Inc
Go

Health Care : Biotechnology | Mid Cap Growth
Company profile

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's commercial products and pipeline of investigational ribonucleic acid (RNA) interference (RNAi) therapeutics are focused in four strategic therapeutic areas (STArs): Genetic Medicines, Cardio-Metabolic Diseases, Hepatic Infectious Diseases and central nervous system/Ocular Diseases. The Company's RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). The ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin amyloidosis. The GIVLAARI is used to reduce induced liver aminolevulinic acid synthase 1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease manifestations of acute hepatic porphyria. The OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1. The Leqvio is used for the treatment of adults with hypercholesterolemia.

Closing Price
$148.50
Day's Change
0.50 (0.34%)
Bid
--
Ask
--
B/A Size
--
Day's High
152.42
Day's Low
142.69
Volume
(Light)
Volume:
457,129

10-day average volume:
740,048
457,129

Bragar Eagel & Squire is Investigating Certain Officers and Directors of CarLotz, HyreCar, Cassava, and Katapult on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

9:00 pm ET November 2, 2021 (Globe Newswire) Print

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors of CarLotz, Inc. (NASDAQ: LOTZ), HyreCar Inc. (NASDAQ: HYRE), Cassava Sciences, Inc. (NASDAQ: SAVA), and Katapult Holdings, Inc. (NASDAQ: KPLT) on behalf of long-term stockholders. More information about each potential case can be found at the link provided.

CarLotz, Inc. (NASDAQ: LOTZ)

Bragar Eagel & Squire is investigating certain officers and directors of CarLotz, Inc. following a class action complaint that was filed against CarLotz on July 8, 2021.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants made material misrepresentations concerning the following: (1) that, due to a surge in inventory during the second half of fiscal 2020, CarLotz was experiencing a "logjam" resulting in slower processing and higher days to sell; (2) that, as a result, the Company's gross profit per unit would be negatively impacted; (3) that, to minimize returns to the corporate vehicle sourcing partner responsible for more than 60% of CarLotz's inventory, the Company was offering aggressive pricing; (4) that, as a result, CarLotz's gross profit per unit forecast was likely inflated; (5) that this Company's corporate vehicle sourcing partner would likely pause consignments to the Company due to market conditions, including increasing wholesale prices; and (6) as a result, Defendants' statements about its business, operations, and prospects were materially false and misleading and/or lacked reasonable basis at all relevant times.

To learn more about our investigation into CarLotz go to: https://bespc.com/cases/LOTZ

HyreCar Inc. (NASDAQ: HYRE)

Bragar Eagel & Squire is investigating certain officers and directors of HyreCar Inc. following a class action complaint that was filed against HyreCar on August 27, 2021.

The complaint alleges that, throughout the Class Period, defendants made false and misleading statements and failed to disclose that: (i) HyreCar had materially understated its insurance reserves; (ii) HyreCar had systematically failed to pay valid insurance claims incurred prior to the Class Period; (iii) HyreCar had incurred significant expenses transitioning to its new third-party insurance claims administrator and processing claims incurred from prior periods; (iv) HyreCar had failed to appropriately price risk in its insurance products and was experiencing elevated claims incidence as a result; (v) HyreCar had been forced to dramatically reform its claims underwriting, policies, and procedures in response to unacceptably high claims severity and customer complaints; and (vi) as a result, HyreCar's operations and prospects were misrepresented because HyreCar was not on track to meet the financial estimates provided to investors during the Class Period, and such estimates lacked a reasonable basis in fact, including HyreCar's purported gross margin, earnings before interest, taxes, depreciation, and amortization ("EBITDA"), and net loss trajectories.

To learn more about our investigation into HyreCar go to: https://bespc.com/cases/HYRE

Cassava Sciences, Inc. (NASDAQ: SAVA)

Bragar Eagel & Squire is investigating certain officers and directors of Cassava Sciences, Inc. following a class action complaint that was filed against Cassava on August 27, 2021.

The complaint alleges that, throughout the Class Period, defendants made false and misleading statements and failed to disclose that: (i) the quality and integrity of the scientific data supporting Cassava Sciences' claims for simulfilam's efficacy had been overstated; (ii) the scientific data supporting Cassava Sciences' claims for simulfilam's efficacy were biased; and (iii) as a result, defendants' positive statements during the Class Period about Cassava Sciences' business metrics and financial prospects and the likelihood of U.S. Food and Drug Administration ("FDA") approval were false and misleading and/or lacked a reasonable basis.

To learn more about our investigation into Cassava go to: https://bespc.com/cases/SAVA

Katapult Holdings, Inc. (NASDAQ: KPLT)

Bragar Eagel & Squire is investigating certain officers and directors of Katapult Holdings, Inc. following a class action complaint that was filed against Katapult on August 17, 2021.

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Katapult was experiencing declining e-commerce retail sales and consumer spending, (2) that despite Katapult's assertions that it was clear and compelling value proposition to both consumers and merchants, transforming the way nonprime consumers shop for essential goods and enabling merchant access to this underserved segment, Katapult lacked visibility into its consumers' future buying behavior; and (3) as a result, Defendants' statements about its business, operations, and prospects were materially false and misleading and/or lacked reasonable basis at all relevant times.

To learn more about our investigation into Katapult go to: https://bespc.com/cases/KPLT

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:

Bragar Eagel & Squire, P.C.

Brandon Walker, Esq.

Alexandra B. Raymond, Esq.

(212) 355-4648

investigations@bespc.com

www.bespc.com

https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg

https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg

comtex tracking

COMTEX_396252570/2010/2021-11-02T21:00:01

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.